Roche Signs an Exclusive Worldwide Option and License Agreement with Rheos Medicines to Develop and Commercialize Therapies for Immunometabolism

Roche Reports Results of Venclexta/Venclyxto (venetoclax) in P-III CLL14 Study for Chronic Lymphocytic Leukemia #ASCO2019


  • Rhoes to receive $42.5M up front, milestones $90M for specified research and preclinical development plus option fees, $660M milestones based on development, regulatory and sales plus royalties on sales. Roche to get exclusive option to license for defined no. of candidates while Rhoes will conduct research to discover and develop novel candidates in immunometabolism
  • The companies will jointly share the WW development and US commercialization rights for certain candidates where Rhoes to get financial compensation within the US and Ex-US commensurate with the share of its financial investment in development and commercialization
  • The focus of the collaboration is to discover, develop and commercialize therapies in immunometabolism and will accelerate the translation of insights for therapies to treat autoimmune and inflammatory diseases

Click here to read full press release/ article | Ref: PRNewswire | Image: Behance